ex.VAT:
VAT:
inc.VAT:

Register now!
Wednesday, July 2, 2014Jurisprudence

Cosmetic short news - Anti-ageing claims: L'Oreal reaches settlement with US FTC

undefined

Latest cosmetics news in brief - Anti-ageing claims: L'Oreal reaches settlement with US FTC - Nanos: the FDA Guidance - Avon to cut 600 jobs - L'Oreal to acquire NYX Cosmetics brand - Reach: Candidate list updated with four new SVHCs - Illinois bans plastic microbeads - China: 2nd version of the inventory of existing ingredients…

Reading time
~ 61 minutes

July, 2 - Anti-ageing claims: L'Oreal reaches settlement with US FTC
L'Oreal reached a proposed settlement with the US Federal Trade Commission (FTC) that would end an inquiry regarding advertising claims linked to two antiwrinkle products (Paris Youth Code and Genifique from Lancome brand). L'Oréal claimed that its products were clinically proven to boost genes' activity and stimulate the production of youth proteins that would cause "visibly younger skin in just 7 days". L'Oréal is now prohibited from making these claims, " not supported by scientific evidence ", according to the FTC. The cosmetic maker said the advertising claims related to its Youth Code and Genifique were discontinued some time ago.

June, 30 - Nanos: the FDA Guidance
FDA publishes a safety of nanomaterials in cosmetic products guidance. FDA recommends that safety assessments for cosmetic products containing nanomaterials addresses a number of factors including physicochemical characteristics, agglomeration and size distribution in the final product, potential routes of exposure to the nanomaterials, dosimetry for in vitro and in vivo toxicology studies, in vitro and in vivo toxicological data on nanomaterial ingredients and their impurities, dermal penetration, potential inhalation, irritation (skin and eye) and sensitization studies, mutagenicity/genotoxicity studies. The guidance invites manufacturers …

This content is only available to subscribersPREMIUM, PRO, STARTUP and TPE

Already subscribed?Log in

Discover our subscriptions

Actives innovation 2024

JurisprudenceOther articles